comparemela.com

Latest Breaking News On - Antineoplastic drug - Page 1 : comparemela.com

ILD Not Increased With MTX in Patients With Dermatomyositis

Treatment with methotrexate was not associated with an increased risk for interstitial lung disease (ILD) in patients with dermatomyositis.

New yorkUnited statesJillt shahYork university langone healthNational institutesHealth sponsored allNew york university langone healthNew york cityBiologic therapyInterstitial lung diseaseAlignant neoplasiaAlignant neoplasmAntineoplastic drugNti cancer agentsMonoclonal antibodyElectronic health records

Combo Therapy Prolongs Survival in Gastric Cancer Patients

The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.

United statesJiafu jiAmerican association for cancer researchDrug administrationInstitute for cancer researchUniversity cancer hospitalAmerican associationCancer researchPeking university cancer hospitalBeijing instituteNew treatment paradigmAdvanced gastricNoncolorectal gastrointestinal cancerOncolorectal gi cancerCombination chemotherapyGastric cancer

FDA Expands Enhertu Indication to HER2-Positive Solid Tumors

The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.

United statesUniversity of texas md anderson cancer centerDrug administrationDaiichi sankyo incDaiichi sankyoCancer centerBoxed warningBreast cancerAlignant breast neoplasmBreast carcinomaBiologic therapyAntineoplastic drugNti cancer agentsNoncolorectal gastrointestinal cancerOncolorectal gi cancerNt specialty

First-Line Highly Effective Therapy Better for Pediatric MS

New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis.

Department of pediatric neurologyUniversity angersExpanded disability status scaleNail benalleguePediatric neurologyMultiple sclerosis msS multiple sclerosisBiologic therapyAntineoplastic drugNti cancer agentsGlatiramer acetateInterferon betaFn betaInterferon betaMonoclonal antibody

How Does Rituximab for Pemphigus Fare in the Long Term?

This marks the first long-term follow-up data from patients in the Ritux 3 trial who received rituximab as a first-line agent.

Haute normandieBillal tedbirtDepartment of dermatologyBiologic therapyAntineoplastic drugNti cancer agentsMonoclonal antibody

vimarsana © 2020. All Rights Reserved.